Work With Us
Contact Us
Work With Us
Contact Us
Search
Search
Close this search box.
Home
About Us
Our Mission and Vision
Meet the Team
Board of Directors
Scientific Advisory Board
Investors
Our Science
About Macrocycles
Introducing MXMO
TM
Our Pipeline
Clinical Trials
Publications
What’s New
Press Releases
Events
Menu
Home
About Us
Our Mission and Vision
Meet the Team
Board of Directors
Scientific Advisory Board
Investors
Our Science
About Macrocycles
Introducing MXMO
TM
Our Pipeline
Clinical Trials
Publications
What’s New
Press Releases
Events
October 23, 2024
CID-078, a First-in-Class Oral Macrocycle CyclinA/B-RxL Inhibitor, Demonstrates Anti-Tumor Activity in E2F-driven Cancers
Downloa
d
